Biogen’s (BIIB) Spinraza, a treatment for the rare and deadly spinal muscular atrophy, got off to a record-setting start, but U.S. growth is already waning, three quarters into the commercial launch.
Spinraza U.S. sales totaled $198 million in the third quarter, almost flat compared to the second quarter, setting off alarms among investors. Biogen’s shares are down 7 percent on Tuesday morning following the biotech firm’s third-quarter earnings report. Ionis Pharmaceuticals (IONS), which received royalties on Spinraza sales, fell 13.5 percent.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Authors
Typical AF comment. Q2 had a $30M pipeline build. Back that out and you get 20% sequential sales growth in US. Sloppy and lazy.
But it’s up 34% overall sequentially and overall results were strong in the report. http://alph.st/b6291dfb